ArticleFrontiers in public health2025
The changing trend and prediction of the burden of anxiety disorder in Chinese population from 2022 to 2035.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anxiety disorders in China and G20 countries: A comparative burden study.The Journal of international medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the disease burden of anxiety disorders globally, in middle SDI countries, and in China using GBD public database. Methods: Data on anxiety disorders were extracted from the GBD database, and GBDR_V2.36 was used for data visualization and plotting. Results: From 1990 to 2021, global anxiety disorder cases and prevalence rose steadily. In 2021, the 30-34 age group had the highest global cases (male:female≈3:7), while DALY rates peaked in 25-29-year-olds. Medium-SDI countries followed similar trends, with peak DALYs in the 20-24 age group. China saw declining prevalence/incidence but rising DALYs, with highest cases in 50-54-year-olds (male:female≈3:5) and DALY rates in 75-84-year-olds. Globally, medium-SDI countries, and China, incidence peaked in 10-14-year-olds. Projections suggest China's anxiety disorder burden will surge through 2035. Conclusion: Globally and in middle SDI countries, prevalence, incidence, and DALY rates increased, with the 30-34 age group showing the highest case burden (women outnumbering men) and peak DALY rates in younger adults (25-29 globally, 20-24 in middle SDI). In contrast, China saw a decline in prevalence and incidence, with the burden peaking later (50-54 for cases, 75-84 for DALYs). Projections indicate rising anxiety disorder burden in China by 2035, necessitating region- and age-specific interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.